Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quyu Yiwei Tablet (祛瘀益胃片) is an approved traditional Chinese medicine (TCM) herbal formulation developed and manufactured by Liaoyuan Yulongyadong Pharmaceutical. The product is composed of twelve herbal ingredients, including Astragalus, Salvia miltiorrhiza, Phellodendron chinense, Paris polyphylla, Licorice, Curcuma zedoaria, Polygonum cuspidatum, Panax notoginseng, Oldenlandia diffusa, Chicken gizzard lining, Atractylodes macrocephala, and Bletilla striata. Based on traditional Chinese medicine theory, the formulation is designed to "benefit the stomach" (Yiwei) and "remove blood stasis" (Quyu), suggesting its primary use in treating chronic gastrointestinal conditions such as gastritis or gastric ulcers associated with blood stasis. It is administered orally as a film-coated tablet.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Quyu Yiwei Tablet.